Atherosclerosis

Clinical Trial Finder

Many patients with atherosclerosis are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Safety and Efficacy of the Combo Bio-engineered Sirolimus-eluting Stent Versus the Nano Polymer-free Sirolimus-eluting Stent in the Treatment of Patients With de Novo Stenotic Lesions

Condition:   Coronary Arteriosclerosis
Interventions:   Device: OrbusNeich Combo stent™;   Device: sirolimus-eluting stent system
Sponsors:   OrbusNeich;   CCRF (Beijing) Inc., Beijing, China.;   OrbusNeich Medical (Shenzhen), Co. Ltd.
Recruiting - verified September 2015

Remote Ischemic Conditioning for Avoiding Recurrence of Symptomatic Intracranial Atherosclerotic Stenosis (sICAS)

Condition:   Intracranial Atherosclerosis
Interventions:   Device: Doctormate® (200mmHg);   Device: Doctormate® (60mmHg)
Sponsor:   Ji Xunming
Not yet recruiting - verified August 2015

Sitagliptin Therapy and Kinetics of Inflammatory Markers

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Placebo
Sponsors:   Laval University;   Merck Sharp & Dohme Corp.
Completed - verified August 2015

Low InTensity Exercise Intervention in PAD

Condition:   Peripheral Artery Disease
Interventions:   Behavioral: Exercise;   Other: Attention control
Sponsors:   Northwestern University;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified August 2015

Safety & Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold

Condition:   Coronary Artery Disease
Intervention:   Device: Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold
Sponsor:   REVA Medical, Inc.
Recruiting - verified August 2015

Delivery of Yamani-15/5 Chemical Solution for PAD

Condition:   Peripheral Arterial Disease
Intervention:   Drug: Yamani-15/5 chemical solution
Sponsor:   Mayo Clinic
Recruiting - verified August 2015

Impact of Chronic Kidney Disease on the Effects of Ticagrelor in Patients With Diabetes and Coronary Artery Disease

Conditions:   Coronary Artery Disease;   Diabetes Mellitus
Intervention:   Drug: ticagrelor
Sponsor:   University of Florida
Not yet recruiting - verified August 2015

Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia

Condition:   Hyperlipidemia
Intervention:   Drug: ARI-3037MO
Sponsor:   Arisaph Pharmaceuticals Inc
Recruiting - verified August 2015

The Effect of Blood Pressure on Cerebral Perfusion During Vascular Surgery

Conditions:   Anesthesia;   Peripheral Arterial Diseases
Interventions:   Other: MAP maintained at 80 mmHg;   Other: MAP maintained at 60 mmHg
Sponsor:   Rigshospitalet, Denmark
Recruiting - verified August 2015

Attentional Capacity and Working Memory in Coronary Artery Disease Patients: Impact of the Presence of a Sleep Apnea Syndrome and Chronic Effects of Treatment With CPAP

Conditions:   Obstructive Sleep Apnea;   Acute Coronary Syndrome
Intervention:   Device: CPAP treatment
Sponsor:   Centre Hospitalier Universitaire de Saint Etienne
Recruiting - verified August 2015

In-Stent Restenosis Post-Approval Study

Conditions:   Peripheral Artery Disease;   Vascular Disease
Intervention:   Device: Gore VIABAHN Endoprosthesis
Sponsor:   W.L.Gore & Associates
Not yet recruiting - verified September 2015

Elutax-SV Drug-eluting Balloons for Below-the-knee Treatment

Conditions:   Critical Limb Ischemia;   Peripheral Artery Disease
Intervention:   Device: Angioplasty Paclitaxel-eluted balloon catheter ELUTAX SV
Sponsors:   Jena University Hospital;   KKS Netzwerk;   Aachen Resonance GmbH
Not yet recruiting - verified August 2015

Effectiveness of Paclitaxel-coated Luminor® Balloon Catheter Versus Uncoated Balloon Catheter in the Arteria Femoralis Superficialis

Condition:   Peripheral Arterial Disease
Interventions:   Device: Transluminal Angioplasty with Paclitaxel-coated Luminor® Balloon Catheter in the Superficial Femoral and Popliteal Arteries;   Device: Transluminal Angioplasty with and non-coated (CE-marked) plain old angioplasty balloon (POBA) catheter
Sponsors:   Jena University Hospital;   iVascular S.L.U.;   KKS Netzwerk
Not yet recruiting - verified August 2015

A Study to Evaluate the Efficacy and Safety of Rosuvastatin in the Treatment of the Carotid Atherosclerotic Plaques

Condition:   Carotid Atherosclerosis
Interventions:   Drug: Rosuvastatin (5mg,10mg,20mg);   Drug: Rosuvastatin 5mg
Sponsors:   Wei Liu;   Xue-Qiao Zhao, MD, FACC. University of Washington;   AstraZeneca;   Beijing Clinstech-med consulting Co., Ltd
Recruiting - verified August 2015

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

Condition:   Peripheral Artery Disease
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban-Placebo
Sponsors:   Bayer;   Janssen Research & Development, LLC;   Colorado Prevention Center (CPC), Denver, Colorado, USA
Recruiting - verified September 2015

PeRiodontal Treatment to Eliminate Minority InEquality and Rural Disparities in Stroke

Conditions:   Periodontal Disease;   Stroke;   TIA
Interventions:   Procedure: Intensive dental treatment;   Procedure: Standard dental treatment;   Drug: Arestin
Sponsors:   University of South Carolina;   University of North Carolina, Chapel Hill
Not yet recruiting - verified September 2015

CER-001 Atherosclerosis Regression ACS Trial

Condition:   Acute Coronary Syndromes
Interventions:   Drug: CER-001;   Drug: Placebo
Sponsors:   Cerenis Therapeutics, SA;   South Australian Health and Medical Research Institute
Recruiting - verified August 2015

Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel

Condition:   Coronary Disease
Interventions:   Drug: Ticagrelor;   Drug: Clopidogrel
Sponsor:   Yongjian Wu
Recruiting - verified August 2015

FAST Feasibility Study

Condition:   Coronary Artery Disease
Intervention:   Device: Boston Scientific Fully Absorbable Scaffold
Sponsor:   Boston Scientific Corporation
Recruiting - verified August 2015

Coronary InterventionS in HIgh-Risk PatiEnts Using a Novel Percutaneous Left Ventricular Support Device (SHIELD II)

Condition:   Coronary Artery Disease
Interventions:   Device: HeartMate PHP;   Device: Abiomed Impella® Recover® LP 2.5
Sponsor:   Thoratec Corporation
Recruiting - verified September 2015

Acute Safety, Deliverability and Efficacy of the Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Patients According to Indication for Use (CHINA RESOLUTE INTEGRITY STUDY)

Conditions:   Ischemic Heart Disease;   Cardiovascular Diseases;   Arteriosclerosis;   Coronary Artery Disease
Intervention:   Device: Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System
Sponsor:   Medtronic Vascular
Active, not recruiting - verified September 2015

Optimal Lesion Preparation With Non-compliant Balloons Before Implantation Of Bioresorbable Scaffolds (OPreNBiS)

Conditions:   Coronary Artery Disease;   Angina;   Unstable Angina;   Stable Angina
Interventions:   Device: Predilatation with OPN NC balloon catheter.;   Device: Predilatation with standard compliant balloon.;   Device: Absorb BVS implantation.;   Procedure: Treated segment visualization by OCT.;   Other: Clinical FU at 12 months.
Sponsor:   SIS Medical AG
Recruiting - verified August 2015

Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine

Condition:   Coronary Artery Disease
Interventions:   Drug: Methylnaltrexone;   Other: Placebo;   Drug: Morphine;   Drug: Ticagrelor
Sponsor:   University of Florida
Recruiting - verified September 2015

Differential Effect of High (200μg/kg/Min) Adenosine Dose on Fractional Flow Reserve in Patients Presenting Variation of FFR ≥0.05 During the Usual Dose of Adenosine Infusion (140μg/kg/Min).

Condition:   Coronary Artery Disease
Intervention:   Drug: Adenosine infusion at 200μg/Kg/min
Sponsor:   University of Patras
Recruiting - verified August 2015

Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes Trial

Conditions:   Dipeptidyl-Peptidase 4 Inhibitors;   LDL Cholesterol;   Glycosylated Hemoglobin;   Diabetes Mellitus;   Coronary Disease
Interventions:   Drug: Anagliptin;   Drug: Sitagliptin
Sponsor:   Institute for Clinical Effectiveness, Japan
Recruiting - verified August 2015

Chest Pain Perception and Capsaicin Sensitivity in Patients With Acute Cardiac Ischemia

Condition:   Chest Pain
Intervention:   Drug: Capsaicin
Sponsor:   Bassett Healthcare
Active, not recruiting - verified August 2015

Randomized Phase IIb Trial of DVC1-0101

Conditions:   Intermittent Claudication;   Peripheral Arterial Disease
Intervention:   Drug: DVC1-0101
Sponsors:   Kyushu University;   CPC Clinical Research (Collorado, USA);   Iberica Co. Ltd. (Fukuoka, Japan);   Ministry of Health, Labour and Welfare, Japan
Recruiting - verified September 2015

Efficacy and Safety of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease

Conditions:   Peripheral Arterial Disease;   Diabetic Foot
Interventions:   Biological: 3 x 10^6 cells;   Biological: 10 x 10^6 cells;   Biological: 30 x 10^6 cells;   Other: Placebo
Sponsor:   Celgene Corporation
Recruiting - verified August 2015

PLATINUM Diversity

Conditions:   Atherosclerosis;   Coronary Artery Disease
Intervention:   Device: Percutaneous coronary intervention (Promus PREMIER)
Sponsor:   Boston Scientific Corporation
Active, not recruiting - verified August 2015

Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR

Condition:   Peripheral Artery Disease (PAD)
Interventions:   Drug: Ticagrelor;   Drug: Comparator
Sponsors:   AstraZeneca;   CPC Clinical Research
Recruiting - verified August 2015

Pharmacological Effects of Crushing Prasugrel in STEMI Patients

Condition:   Coronary Artery Disease
Intervention:   Drug: prasugrel
Sponsor:   University of Florida
Active, not recruiting - verified August 2015

Study Of Costs Realized After Percutaneous Coronary intervenTion Employing Same Day Discharge

Condition:   Coronary Artery Disease
Intervention:   Procedure: Same day discharge
Sponsors:   Saint Joseph Mercy Health System;   Michigan Heart;   Blue Cross Blue Shield of Michigan Foundation
Terminated - verified August 2015

Non-invasive Computer-Aided Phenotyping of Vasculopathy

Conditions:   Carotid Atherosclerosis;   Peripheral Arterial Disease
Intervention:  
Sponsor:   Elucid Bioimaging Inc.
Recruiting - verified August 2015

Using Feedback Reports to Improve Medication Adherence

Conditions:   Coronary Artery Disease;   Adherence
Interventions:   Behavioral: Individual Feedback;   Behavioral: Feedback Friend
Sponsor:   Philadelphia Veterans Affairs Medical Center
Active, not recruiting - verified August 2015

Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia

Condition:   Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
Interventions:   Drug: Epanova® (omega-3 carboxylic acids);   Drug: corn oil control
Sponsors:   AstraZeneca;   The Cleveland Clinic
Recruiting - verified August 2015

In Vitro Pharmacodynamic Effects of Cangrelor in Ticagrelor Treated Patients

Condition:   Coronary Artery Disease
Interventions:   Drug: Ticagrelor 180mg;   Drug: Ticagrelor 90mg
Sponsors:   University of Florida;   The Medicines Company
Recruiting - verified May 2015

A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function:

Condition:   Coronary Artery Disease
Interventions:   Drug: Prasugrel;   Drug: Ticagrelor
Sponsor:   University of Florida
Recruiting - verified September 2015

Prospective Assessment of Efficacy and Safety of Drug Eluting Stents

Condition:   Coronary Heart Disease
Intervention:  
Sponsor:   China National Center for Cardiovascular Diseases
Completed - verified August 2015

Post Market Surveillance Study of the Wingspan Stent System

Condition:   Intracranial Atherosclerosis
Intervention:   Device: Wingspan Stent System
Sponsor:   Stryker Neurovascular
Recruiting - verified August 2015

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events

Condition:   Hyperlipidemia
Interventions:   Drug: Bococizumab (PF-04950615; RN316);   Other: Placebo
Sponsor:   Pfizer
Recruiting - verified September 2015

A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia

Condition:   Heterozygous Familial Hypercholesterolemia
Interventions:   Drug: Bococizumab (PF-04950615;RN316);   Other: Placebo
Sponsor:   Pfizer
Recruiting - verified September 2015

First in Man Study of the DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold (BIOSOLVE-II)

Conditions:   Coronary Artery Disease;   Coronary Artery Stenosis
Intervention:   Device: Percutaneous Coronary Intervention (DREAMS) stenting
Sponsor:   Biotronik AG
Active, not recruiting - verified September 2015

Optimizing Antithrombotic Care in Patients With AtriaL fibrillatiON and Coronary stEnt (OAC-ALONE) Study

Conditions:   Atrial Fibrillation;   Coronary Artery Disease
Intervention:   Drug: OAC alone
Sponsors:   Satoshi Shizuta;   Research Institute for Production Development;   Daiichi Sankyo Co., Ltd.
Recruiting - verified August 2015

Effect of Atorvastatin on Fractional Flow Reserve in Coronary Artery Disease

Condition:   Coronary Artery Disease
Intervention:   Drug: Atorvastatin
Sponsors:   Keimyung University Dongsan Medical Center;   Seoul National University Hospital;   Ulsan University Hospital;   Inje University
Recruiting - verified August 2015

Comparison of the Biolimus A9-eluting Stent With the Zotarolimus -Eluting Stent in Multi-vessel PCI

Condition:   Multivessel Coronary Artery Disease
Intervention:   Procedure: Percutaneous Coronary Intervention
Sponsor:   Keimyung University Dongsan Medical Center
Recruiting - verified August 2015

Multi-center Prospective Study to Evaluate Outcomes of the Moderate to Severely Calcified Coronary Lesions (MACE)

Condition:   Coronary Artery Disease
Intervention:  
Sponsor:   Cardiovascular Systems Inc
Recruiting - verified September 2015

Investigations of the Effect of MK-7 on Bone and Glucose Metabolism and Arterial Calcification

Condition:   Metabolic Bone Disorder
Interventions:   Dietary Supplement: K2 vitamin;   Dietary Supplement: Placebo
Sponsors:   University of Aarhus;   Axellus
Active, not recruiting - verified August 2015

Resolute Integrity US Extended Length Sub-Study(RI-US XL)

Condition:   Coronary Artery Disease
Intervention:   Device: Resolute Integrity Stent
Sponsor:   Medtronic Vascular
Recruiting - verified September 2015

Cognition and Exercise Training

Conditions:   Metabolic Syndrome;   Coronary Heart Disease;   Chronic Heart Failure
Interventions:   Other: high intensity interval training (HIIT);   Other: moderate intensity continuous exercise training
Sponsor:   Montreal Heart Institute
Recruiting - verified August 2015

Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)

Condition:   Coronary Artery Disease
Intervention:   Drug: Gadobutrol (Gadovist, BAY86-4875)
Sponsor:   Bayer
Recruiting - verified September 2015

Long-Term rIsk, Clinical manaGement and Healthcare Resource Utilization of Stable CAD in Post MI Patients

Condition:   Stable Coronary Artery Disease (CAD), Myocardial Infarction
Intervention:  
Sponsor:   AstraZeneca
Active, not recruiting - verified September 2015

OPtimized Stenting Using Intravascular Ultrasound(IVUS) in Long lEsion: Rationale for Simplified criteriA

Conditions:   Coronary Heart Disease;   Diabetes;   Vascular Lesions;   Chronic Total Occlusion of Coronary Artery;   Restenosis
Intervention:   Device: TAXUS™ Element long stent
Sponsors:   Centre Chirurgical Marie Lannelongue;   Cochin Hospital;   Centre Hospitalier de La Rochelle;   University Hospital, Limoges;   Hôpital de la Timone;   Centre Hospitalier Universitaire de Nice;   Centre Hospitalier de PAU;   Rangueil Hospital;   Central Hospital, Versailles
Recruiting - verified August 2015

Optical Frequency Domain Imaging (OFDI) Assessed Strut Coverage of New Terumo DES

Condition:   Coronary Artery Disease
Intervention:   Device: TCD-10023 drug eluting stent
Sponsor:   Terumo Europe N.V.
Active, not recruiting - verified September 2015

The Psoriasis, Atherosclerosis, and Cardiometabolic Disease Initiative (PACI)

Conditions:   Metabolic Disease;   Cardiovascular Disease;   Inflammation
Intervention:  
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   University of Pennsylvania
Recruiting - verified November 2014

A Study to Evaluate the Effect of Aleglitazar on Cardiac Energetics and Function in Patients With Type 2 Diabetes Mellitus and no History of Coronary Artery Disease

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

China PEACE-Prospective AMI Study

Condition:   Coronary Heart Disease
Intervention:  
Sponsors:   China National Center for Cardiovascular Diseases;   Ministry of Health, China
Completed - verified August 2015

China PEACE-Prospective PCI Study

Condition:   Coronary Heart Disease
Intervention:  
Sponsors:   China National Center for Cardiovascular Diseases;   Ministry of Health, China
Completed - verified August 2015

Effect of Mipomersen on LDL-Cholesterol Levels in Patients Treated by Regular Apheresis

Conditions:   Atherosclerosis;   LDL-hypercholesterolemia
Intervention:   Drug: mipomersen
Sponsor:   Ludwig-Maximilians - University of Munich
Completed - verified September 2015

A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease

Condition:   Coronary Heart Disease
Interventions:   Drug: MPSK3169A;   Drug: MPSK3169A;   Drug: MPSK3169A;   Drug: MPSK3169A;   Drug: MPSK3169A;   Drug: Placebo
Sponsor:   Genentech, Inc.
Completed - verified September 2015

A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease

Condition:   Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)
Interventions:   Other: Background care;   Drug: Placebo;   Drug: dalcetrapib
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

Prospective Study of End Stage Renal Disease Patients With Coronary Artery Disease Treated by Oral Nicorandil

Conditions:   Coronary Artery Disease;   End Stage Renal Disease
Intervention:   Drug: Nicorandil (15mg/day)
Sponsor:   Kumamoto University
Active, not recruiting - verified August 2015

A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)

Condition:   Coronary Heart Disease
Interventions:   Drug: dalcetrapib;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

A Study to Assess the Safety, Tolerability, and Effects of MK-0974 (Telcagepant) on Exercise Tolerance in Patients With Stable Angina (MK-0974-014)

Conditions:   Angina Pectoris;   Coronary Heart Disease;   Calcitonin Gene-related Peptide Receptor
Interventions:   Drug: telcagepant;   Drug: Placebo to telcagepant
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified September 2015

Atorvastatin for Preventing Occlusion and Restenosis After Intracranial Artery Stenting

Condition:   CVD
Intervention:   Drug: atorvastatin
Sponsor:   Jinling Hospital, China
Completed - verified September 2015

A Study of RO4905417 in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery

Condition:   Coronary Heart Disease, Graft Occlusion, Vascular
Interventions:   Drug: Placebo;   Drug: RO4905417
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

Screen of DM by OGTT in Subjects Receiving CAG or MDCT for CAD

Conditions:   Diabetes Mellitus;   Coronary Artery Disease
Intervention:   Drug: Acarbose
Sponsor:   Taichung Veterans General Hospital
Recruiting - verified September 2015

Combined Non-invasive Coronary Angiography and Myocardial Perfusion Imaging Using 320 Detector Computed Tomography

Conditions:   Arterial Occlusive Diseases;   Coronary Disease;   Heart Diseases;   Myocardial Ischemia;   Vascular Diseases;   Arteriosclerosis;   Ischemia;   Coronary Artery Disease
Interventions:   Procedure: 320 Volume Detector Computed Tomography;   Other: Other: Multidetector Computed Tomography - 320 detectors
Sponsors:   Johns Hopkins University;   Toshiba America Medical Systems, Inc.
Active, not recruiting - verified September 2015

Effects of Telmisartan on Ischemic Cardiovascular Events in High-risk Hypertensive Patients

Conditions:   Acute Myocardial Infarction;   Angina Pectoris;   Myocardial Ischemia;   Acute Coronary Syndrome;   Hypertension
Interventions:   Drug: Micardis (Telmisartan);   Drug: Blopress (Candesartan)
Sponsor:   Kyoto Prefectural University of Medicine
Terminated - verified September 2015

A Multiple Ascending Dose Study of RO4905417 in Healthy Volunteers and Patients With Peripheral Arterial Disease (PAD).

Condition:   Peripheral Arterial Disease (PAD)
Interventions:   Drug: RO4905417;   Drug: RO4905417;   Drug: RO4905417;   Drug: placebo;   Drug: placebo;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019)

Conditions:   Coronary Heart Disease (CHD);   CHD Risk-Equivalent Disease
Interventions:   Drug: anacetrapib;   Drug: Comparator: placebo
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified September 2015

A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patients

Condition:   Coronary Heart Disease
Interventions:   Drug: Placebo;   Drug: dalcetrapib
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease

Condition:   Coronary Heart Disease
Interventions:   Drug: Placebo;   Drug: dalcetrapib
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome

Condition:   Coronary Heart Disease
Interventions:   Drug: Evidence-based medical care for Acute Coronary Syndrome;   Drug: Placebo;   Drug: dalcetrapib
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

Comparison of Effects of Telmisartan and Valsartan on Neointima Volume in Diabetes

Conditions:   Hypertension;   Diabetes;   Coronary Artery Disease
Interventions:   Drug: telmisartan;   Drug: valsartan
Sponsor:   Korea University Anam Hospital
Completed - verified September 2015

Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED)

Conditions:   Hypercholesterolemia;   Metabolic Syndrome
Interventions:   Drug: ezetimibe (+) simvastatin;   Drug: Comparator: atorvastatin calcium;   Drug: Comparator:  Placebo (unspecified)
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified September 2015

Database Registry of the Intermountain Heart Collaborative Study

Conditions:   Coronary Artery Disease;   Electrophysiology;   Cardiovascular Disease
Intervention:  
Sponsor:   Intermountain Health Care, Inc.
Recruiting - verified August 2015

A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381

Condition:   Coronary Heart Disease
Interventions:   Drug: Placebo;   Drug: dalcetrapib
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.

Condition:   Coronary Heart Disease
Interventions:   Drug: Placebo;   Drug: dalcetrapib
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

Environmental and Biological Monitoring Pilot Study for Polycyclic Aromatic Hydrocarbons in Linxian, China

Condition:   Esophageal Cancer
Intervention:  
Sponsor:   National Cancer Institute (NCI)
Completed - verified August 2014

EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)

Conditions:   Myocardial Ischemia;   Acute Coronary Syndrome
Interventions:   Drug: Eptifibatide (Integrilin);   Drug: Placebo
Sponsors:   Merck Sharp & Dohme Corp.;   Duke Clinical Research Institute
Completed - verified September 2015

Get CardioSmart

You're Invited